Keros Therapeutics, Inc. (KROS) vs Nautilus Biotechnolgy, Inc. (NAUT)
A side-by-side comparison of Keros Therapeutics, Inc. and Nautilus Biotechnolgy, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
KROS
Keros Therapeutics, Inc.
$11.19HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
NAUT
Nautilus Biotechnolgy, Inc.
$1.92HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — KROS vs NAUT
growth of $100 · dividends reinvested · last 6yKROS -68.3% (-17.4%/yr)NAUT -82.1% (-24.9%/yr)KROS compounded faster over this window
KROS NAUT
KROS vs NAUT: by the numbers
- •NAUT is the larger company ($244M vs $222M market cap).
- •Both run net losses; KROS's is the smaller (-553.88% vs -29747.89% net margin).
Metrics side by side
Valuation
| Metric | KROS | NAUT |
|---|---|---|
| P/S ratio | 14.78 | 1285.95 |
| P/B ratio | 0.85 | 1.86 |
Profitability
| Metric | KROS | NAUT |
|---|---|---|
| Gross margin | 94.68% | 0.00% |
| Operating margin | 28.94% | 0.00% |
| Net margin | -553.88% | -29747.89% |
| ROE | -31.70% | -43.11% |
| ROIC | -36.49% | -40.52% |
Growth (annualized)
| Metric | KROS | NAUT |
|---|---|---|
| Revenue CAGR (5Y) | 172.50% | N/A |
| Total return CAGR (5Y) | -21.98% | -20.56% |
Frequently asked
- How have KROS and NAUT total returns compared?
- Over the past 5 years, KROS delivered -21.98% and NAUT delivered -20.56% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Keros Therapeutics ROENautilus Biotechnolgy ROEKeros Therapeutics operating marginNautilus Biotechnolgy operating marginKeros Therapeutics revenue growthNautilus Biotechnolgy revenue growthKeros Therapeutics free cash flowNautilus Biotechnolgy free cash flow
Keros Therapeutics & Nautilus Biotechnolgy appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.